A vaccine for the elimination of the deadly corona virus (corona vaccine update) has reached a miracle. This vaccine (AZD1222) from Oxford University and pharmaceutical company AstraZeneca has recorded its first victory over Corona. The vaccine has proved successful in the first and second phase trials. Now the third phase trial is going on. The vaccine will also be trialed in India before its launch in India.
Serum Institute of India will play an important role
Serum Institute of India (SII) is also collaborating to develop the Corona vaccine developed by AstraZeneca and Oxford University. The serum is one of the largest pharmaceutical companies in the world. The CEO of this homegrown company, Adar Poonawala, said that the company would apply to the Indian drug regulator for a license to start its clinical trial within a week.
First, 100 million doses to be made, half of India
Indian company Serum Institute of India has already announced that 50 percent of the vaccine it produces will be for India and 50 percent for the rest of the countries. In such a situation, when Oxford’s vaccine is ready, India can get half the consignment. That is 50 crore doses.
When will it come, what can be the price
Adar Poonawala of Serum Institute of India (SII) made his remarks on this. He said that the Oxford vaccine could be ready by the end of this year. Talking on the price, he said that it is too early to talk about it but it is certain that the price will be decided according to the reach of the common people. It is believed that the government should make it reach people without any charge.
The trial will also be conducted in India before launch
This vaccine has just been the result of the first and second phases. Although the third phase trial has started in Brazil. 5 thousand people are participating in it. A similar trial will be held in South Africa. Then the Serum Institute of India can also seek approval to conduct the third phase trial in India.
Lakhs of doses will be made in India in the next three months
The Serum Institute, along with Oxford, has already made preparations for making the vaccine. There are plans to make millions of doses in the next three months. These will be made in India only. The company will soon apply for a license. The firm will make this vaccine for low and middle-income countries. The company will initially prepare a billon dose. Which will be given to middle and low-income countries. It also includes India.
56 days, trial on 1 thousand people
British researchers started testing this vaccine named ChAdOx1 nCoV-19 in April. In a total of 56 days of trial, between April 23 and May 21, a total of 1055 people were tried. It was found that the vaccine is not only safe but also making antibodies against the virus.
The vaccine showed a two-way advantage
The results of the first and second phases of this vaccine have been published in the British magazine Lancet. Trials conducted on a total of 1107 people between 18 and 55 years of age showed that this vaccine showed a two-way advantage. Also made antibodies in the body and also worked to strengthen the immune system.
Paracetamol-like drug eradicated side effects
The report also described this vaccine as being good on safety, saying that no major side effects of the vaccine were observed. There were minor side effects, which were cured with medication such as paracetamol.
The vaccine also contains booster dose
The Oxford vaccine also has a booster dose, given after 28 days. Reports show that antibodies were found to be better and stronger than those given booster doses. Therefore it can also be said that booster dose can also be given for strong antibodies.